Company Filing History:
10 out of 810 
2 out of 1,168 Years Active: 2004-2017
Title: Hagit Eldar-Finkelman: Innovator in Glycogen Synthase Kinase-3 Inhibitors
Introduction
Hagit Eldar-Finkelman is a prominent inventor based in Shoham, Israel. He has made significant contributions to the field of biochemistry, particularly in the development of peptide inhibitors for glycogen synthase kinase-3 (GSK-3). With a total of 10 patents to his name, his work has the potential to impact various medical conditions associated with GSK-3 activity.
Latest Patents
Eldar-Finkelman's latest patents focus on novel peptide inhibitors of GSK-3. These inhibitors are designed to interact with the enzyme's catalytic site, acting as disease-selective inhibitors for conditions linked to increased GSK-3 activity or expression. Each peptide is composed of no more than 15 amino acid residues and features a specific ZXXXZ(p) recognition motif. This motif includes a phosphorylated serine or threonine residue, allowing for targeted inhibition. Additionally, methods for identifying substrate-competitive peptide inhibitors through computational modeling and screening are also disclosed in his patents.
Career Highlights
Throughout his career, Hagit Eldar-Finkelman has worked with notable institutions, including Tel Aviv University Future Technology Development and Ramot at Tel Aviv University Ltd. His research has contributed to advancements in therapeutic strategies for diseases related to GSK-3.
Collaborations
Eldar-Finkelman has collaborated with esteemed colleagues, including Moshe Portnoy and Miriam Eisenstein. Their combined expertise has furthered the development of innovative solutions in the field of biochemistry.
Conclusion
Hagit Eldar-Finkelman's work in developing GSK-3 inhibitors showcases his dedication to advancing medical science. His innovative approaches and collaborations highlight the importance of research in addressing complex health challenges.